Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical compositions comprising alpelisib

一种药学、片剂的技术,应用在新分散片领域,能够解决不切实际、不理想、无法方便地吞咽等问题

Inactive Publication Date: 2017-08-29
NOVARTIS AG
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, oral administration of the drug in solid tablet form is undesirable or impractical for certain patient populations
In particular, children, elderly patients, and patients with head and neck cancer may not be able to swallow these tablets conveniently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising alpelisib
  • Pharmaceutical compositions comprising alpelisib
  • Pharmaceutical compositions comprising alpelisib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0160] Embodiment 1: Dispersible tablet preparation (50mg dispersible tablet, disintegration time is less than 3 minutes)

[0161]

[0162]

[0163] The tablets are prepared as follows: Granules with inner and outer phases are formed via (i.) Wet granulation of the inner phase comprising 50.00 mg Compound I, 23.00 mg Microcrystalline Cellulose (Avicel PH101), 23.00 mg Mandew Alcohol, 3.0 mg sodium starch glycolate and 3.00 mg low-substituted hydroxypropyl cellulose, then (ii.) by mixing the resulting mixture with 4.06 mg sodium starch glycolate and 15.86 mg microcrystalline cellulose (Avicel PH102) sieved, The resulting mixture was then mixed with 5.08 mg of sieved sodium stearyl fumarate to form the external phase.

[0164] Tablets are obtained by compressing the mixture obtained in step (ii) above. Above step (ii) gained composition is used Compression on a 102i rotary tablet press, using a compression force of about 5-11 kN (preferably about 8 kN), with a 7mm diam...

Embodiment 2

[0167] Embodiment 2: dispersible tablet preparation (200mg dispersible tablet, disintegration time is less than 3 minutes)

[0168]

[0169] The tablets are prepared by wet granulation of the inner phase via (i.) wet granulation of the inner phase comprising 200.00 mg of compound I, 92.00 mg of microcrystalline cellulose (Avicel PH101 ), 92.00 mg of mannitol, 12.00 mg sodium starch glycolate and 12.00 mg low-substituted hydroxypropyl cellulose, then (ii.) form the external phase by mixing the resulting mixture with sieved 16.24 mg sodium starch glycolate and 63.44 mg microcrystalline cellulose (Avicel pH 102), the resulting mixture was then mixed with 20.32 mg of sieved sodium stearyl fumarate.

[0170] Tablets are obtained by compressing the mixture obtained in step (ii) above. Above step (ii) gained composition is used Compression on a 102i rotary tablet press, using a compression force of about 12-20 kN (preferably about 16 kN), with a 16.0 x 6.3 mm die and standard...

Embodiment 3

[0174] Example 3: Example of disintegration time

[0175] The table below provides examples of disintegration times in minutes for tablets formulated according to Example 1 or Example 2:

[0176]

[0177] In the above test, a particular tablet formulated according to Example 1 or Example 2 was evaluated to determine whether the tablet disintegrated in less than 5 minutes when placed in a liquid medium. Tablet disintegration time was evaluated according to the procedure outlined in European Pharmacopoeia, Eighth Edition, Appendix 8.2, pp. 285-287, Section 2.9.1 (January 2014), which is hereby incorporated by reference in its entirety. Discs were not used in these experiments.

[0178] Complete disintegration was defined as the state of any tablet remaining on the test device screen as a soft mass with no palpable hard core except for insoluble coating fragments.

[0179] Rack assemblies were used for these tests. The basket assembly consisted of 6 open transparent tubes (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to dispersible tablets comprising the compound (S)-Pyrrolidine- 1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The present invention relates to compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1- New dispersible tablet of dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof. Background of the invention [0002] Phosphatidylinositol 3-kinases ("PI-3 kinases" or "PI3Ks") comprise a ubiquitously expressed family of lipid kinases that function as key signal transducers downstream of cell surface receptors and key regulators of cellular metabolism and survival . [0003] Of the two class 1 PI3Ks, class 1A PI3Ks are heterodimers composed of catalytic p110 subunits (α, β, δ isoforms) constitutively linked to regulatory subunits, which can be p85α, p55α, p50α, p85β or p55γ. These catalytic p110 subunits (alpha, beta, delta isoforms) are encoded by three genes (PIK3CA, PIK3CB and PIK3CD) in humans. Class 1B PI3Ks have one family member, a heterodimer consisting of the catalytic p1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K47/38A61K47/36A61K31/454A61P35/00A61P35/02
CPCA61K9/0095A61K9/2054A61K9/2059A61K31/454A61K31/4439A61J3/10A61P35/00A61P35/02A61P43/00A61K9/0056A61K9/10A61K9/20A61K47/14A61K47/36A61K47/38A61K9/0053A61K9/2013A61K9/2018A61K9/2095
Inventor F·艾尔巴茨C·科赫哈D·斯丁奇林M·A·M·博克
Owner NOVARTIS AG